2月24日，复宏汉霖（02696）发布公告，公司终止与PT Kalbe Genexine Biologics（下称KGBio）就汉斯状®（斯鲁利单抗注射液）在东南亚、中东及北非地区国家的独家开发及商业化许可权力。
同日，公司与Abbott Products Operations AG（下称Abbott）签订修订的许可协议，扩大原Abbott的许可区域。新增许可区域覆盖亚洲、中东、非洲及东欧等42个国家/地区。许可产品的监管里程碑款项不超4600万美元，商业销售里程碑合计不超8000万美元。
根据协议修订，公司将终止在KGBio终止区域内的独家许可权。KGBio将转让该区域内的上市许可，公司据此支付不超过3375万美元里程碑款项，监管里程碑同步下调。修订后，原协议中的销售里程碑和特许权使用费约定仅适用于印度尼西亚。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.